Clinical Trial

Effect of Quinine Hydrochloride in Overweight Population on Food Intake, Hunger and Gut Peptide Release

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2024 (before its estimated October 29, 2025 completion). Its status may not reflect the trial's current state.
Summary
The worldwide increase in the prevalence of obesity is a cause of great concern. Pharmacological treatment options are being explored at the moment with a major focus on the hormones produced by the gastrointestinal tract which regulate hunger and satiation/satiety. Modulating the release of these hormones via bitter substances reduced appetite-related sensations and gastrointestinal motility in lean female volunteers. Intragastric administration of a quinine-solution has shown to decrease hunger sensations in healthy female volunteers. Now, we want to examine whether this effect is still seen in an overweight female population.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04873011
Lead Sponsor Universitaire Ziekenhuizen KU Leuven
Conditions Obesity
Enrollment 40 participants
Start Date 2020-10-29
Primary Completion 2025-10-29 (estimated)
Study Completion 2025-10-29 (estimated)
Updated on ClinicalTrials.gov 2024-07-03